02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
03:19 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Mutations in hematopoiesis-associated genes could help predict the risk of AML. Genomic sequencing of 124 patients who later developed AML and 686 healthy volunteers identified associations between the disease and mutations in...
23:36 , Apr 10, 2018 |  BC Extra  |  Preclinical News

Researchers identify coding, non-coding driver mutations in MM

Scientists from the Institute of Cancer Research (London, U.K.) identified coding and non-coding driver mutations involved in newly diagnosed multiple myeloma, suggesting the genes could be targeted to treat the disease. The research was published...
21:50 , Dec 1, 2017 |  BC Week In Review  |  Company News

Boehringer launches open-access preclinical platform

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open, free access to select molecules in the preclinical stage. The platform, opn.ME , comprises 19 compounds that Boehringer has deemed suitable...
22:03 , Nov 20, 2017 |  BC Extra  |  Company News

Boehringer launches open-access preclinical platform

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open and free access to select preclinical-stage molecules. The platform, opn.ME , comprises 19 compounds that Boehringer has deemed suitable for preclinical...
14:22 , Apr 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture, and mouse studies suggest inhibiting BCL6 could help treat glioblastoma multiforme (GBM). In patients, high tumor levels of BCL6 were associated with poor survival. In GBM tumor cells...
07:00 , Aug 20, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: BCL6 corepressor (BCOR) gene aberrations as a diagnostic marker for clear cell sarcoma of the kidney

Biomarkers TECHNOLOGY: Gene profiling BCL6 corepressor (BCOR) National Research Institute for Child Health and Development...
07:00 , Oct 11, 2012 |  BC Innovations  |  Strategy

Leukemia team building

The Leukemia & Lymphoma Society has announced its first research partnership with a large biopharma company-a four-year, multimillion-dollar deal with Celgene Corp. to solicit and fund proposals from academics and smaller biotechs. The not-for-profit organization...
07:00 , Aug 2, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Subtype-specific somatic mutations in medulloblastoma Identification of new subtype-specific somatic mutations in medulloblastoma could aid the development of new treatments for the disease. Whole-exome hybrid capture...